Question explored with the scientific record
Conversation so far
- …started from a private conversation
- 1 It is pregabalin
- 2 I think I need to take monjaro
Answered on this page ↓
I think I need to take monjaro
The short version: Mounjaro is a powerful weight-loss drug, but it is not a treatment for pregabalin withdrawal, and starting it while you taper adds a second drug's side effects to a delicate process.
The evidence for Mounjaro (tirzepatide) is real but narrow. In the SURMOUNT-1 extension, people with obesity and prediabetes lost 12% to 20% of their body weight over 176 weeks, versus about 1% on placebo [3]. A 2026 meta-analysis confirms significant weight loss and HbA1c reduction in people with type 2 diabetes [4]. The catch is that the drug works while you take it. When people stop, they regain weight: about 14% of the lost weight came back within a year in the SURMOUNT-4 withdrawal analysis [5]. This is a lifetime drug, not a fix.
The safety data is thinner than the marketing. Gastrointestinal side effects are the main reason people quit, with 12.3% stopping the 15 mg dose versus 5.9% on placebo [3]. The drug also causes lean muscle loss, about 39% of total weight lost in one semaglutide substudy, and rapid weight loss can trigger hair shedding [5, 6]. None of these trials studied people coming off pregabalin. None of them tracked brain fog as an outcome.
The withdrawal risk from pregabalin is the more urgent problem. Abruptly stopping it can cause seizures or psychiatric symptoms even at standard doses [1, 2]. Mounjaro does nothing to protect against that. It changes appetite and blood sugar, not the brain's calcium-channel adaptation to pregabalin.
| Outcome | Tirzepatide | Placebo |
|---|---|---|
| Weight loss at 176 weeks | 12% to 20% [3] | 1.3% [3] |
| Stopped due to side effects (15 mg) | 12.3% [3] | 5.9% [3] |
| Weight regain after stopping | ~14% within a year [5] | - |
My call: taper the pregabalin first, slowly, and only consider Mounjaro after you are stable off it, if weight loss is still your goal. Starting both at once means you cannot tell which drug is causing which side effect. Confidence: moderate on the taper-first sequence, low on Mounjaro helping your brain fog, because no study has tested that.
Sources used 6
-
Psychiatric Symptoms Following Sudden Withdrawal from the Drug Pregabalin
Doctors and pharmacy staff should be aware that psychiatric symptoms may occur after sudden withdrawal from pregabalin, even in standard-dose patients; doses should be tapered rather than stopped suddenly.
DOI: 10.23937/2474-3631/1510044 -
SEİZURE TRİGGERED BY SUDDEN DİSCONTİNUATİON OF PREGABALİN: A CASE REPORT
A 24-year-old male with pregabalin dependence and no history of epilepsy developed a generalized tonic-clonic seizure three days after abruptly discontinuing chronic high-dose (4200 mg/day) pregabalin, with all investigations (labs, MRI, EEG) normal, and no seizure recurrence af…
DOI: 10.70846/nigdetip.1813909 -
Tirzepatide: the most Effective Drug Therapy for Prevention of type 2 Diabetes
In an extension of the SURMOUNT-1 trial, tirzepatide reduced progression to type 2 diabetes by 93% versus placebo over 176 weeks in adults with obesity and prediabetes, and is reported as the most effective drug therapy for diabetes prevention.
DOI: 10.31579/2834-8761/073 -
Management of Overweight and Obese People with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide: A Systematic Review
In a systematic review and meta-regression of randomized controlled trials, tirzepatide significantly reduced body weight and HbA1c compared with placebo or other hypoglycemic drugs in overweight/obese adults with type 2 diabetes, with no significant difference in serious advers…
DOI: 10.57237/j.cmf.2026.01.001 -
The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics
This narrative review argues that in obesity management with incretin mimetics (GLP-1 receptor agonists and GLP-1/GIP co-agonists), pharmacotherapy should be integrated with personalized dietetic and structured exercise interventions to maximize fat loss, preserve lean mass and …
DOI: 10.1159/000548370 -
Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
Rapid systemic metabolic stress from GLP-1 receptor agonists and bariatric surgery can trigger telogen effluvium, a reversible hair shedding response tied to lean-mass loss and metabolic disruption rather than lasting follicular damage.
DOI: 10.62742/2965-7911.2026.3.bjhh38